Bioheart, Inc. Appoints Five-Member Advisory Board to Assist in Development of its New Business Plan
February 29, 2012 at 03:30 pm IST
Share
Bioheart, Inc. announced that it has appointed a five-member advisory board comprised of local and international business, financial and marketing executives to assist in the development of the company's new business plan. The members of the advisory board have successfully grown companies, held C-level positions at public and privately held companies and executed complex million-dollar financial transactions. The five-member advisory board members consist of Gary G. Altman, PhD is a former general manager of a $200 million Global Business Unit at Beckman Coulter -- Danaher Corporation, co-founder and COO of Sequoia Pharmaceuticals, and vice president of strategy, market and business development for Hemostasis Business. Louis Risi, Jr. has owned, operated, acquired and sold numerous business ventures during his 50-year business career. As a successful insurance and manufacturing executive, he served as former president/CEO of National Investors Fire & Casualty Co. and Norin Corporation. Ari Rollnick is principal/founder of kabookaboo. Charles P. Sacher is a founding shareholder with the law firm of Sacher, Martini & Sacher, P.A. Frank L. Young has recently served as CFO with CuRNA.
U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. MyoCell SDF-1 is similar to MyoCell except that the myoblast cells to be injected for use in MyoCell SDF-1 will be modified prior to injection by an adenovirus vector or non-viral vector. Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.
U.S. STEM CELL, INC. 
